SMT202100611T1 - Vaccini individualizzati per il cancro - Google Patents

Vaccini individualizzati per il cancro

Info

Publication number
SMT202100611T1
SMT202100611T1 SM20210611T SMT202100611T SMT202100611T1 SM T202100611 T1 SMT202100611 T1 SM T202100611T1 SM 20210611 T SM20210611 T SM 20210611T SM T202100611 T SMT202100611 T SM T202100611T SM T202100611 T1 SMT202100611 T1 SM T202100611T1
Authority
SM
San Marino
Prior art keywords
cancer
individualized vaccines
individualized
vaccines
Prior art date
Application number
SM20210611T
Other languages
English (en)
Italian (it)
Inventor
Ugur Sahin
Tana Omokoko
Sebastian Kreiter
Mustafa Diken
Jan Diekmann
Cedrik Britten
John Castle
Martin Löwer
Bernhard Renard
Graaf Johannes Hendrikus De
Michael Koslowski
Original Assignee
BioNTech SE
Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2011/002576 external-priority patent/WO2012159643A1/en
Application filed by BioNTech SE, Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh filed Critical BioNTech SE
Priority claimed from EP18199105.0A external-priority patent/EP3473267B1/en
Publication of SMT202100611T1 publication Critical patent/SMT202100611T1/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6804—Nucleic acid analysis using immunogens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/686—Polymerase chain reaction [PCR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6869—Methods for sequencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6869—Methods for sequencing
    • C12Q1/6874—Methods for sequencing involving nucleic acid arrays, e.g. sequencing by hybridisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
    • G16C20/70—Machine learning, data mining or chemometrics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Public Health (AREA)
  • Theoretical Computer Science (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Epidemiology (AREA)
  • Evolutionary Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Artificial Intelligence (AREA)
  • Data Mining & Analysis (AREA)
  • Databases & Information Systems (AREA)
  • Evolutionary Computation (AREA)
  • Software Systems (AREA)
SM20210611T 2011-05-24 2012-05-23 Vaccini individualizzati per il cancro SMT202100611T1 (it)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/EP2011/002576 WO2012159643A1 (en) 2011-05-24 2011-05-24 Individualized vaccines for cancer
EP2012000006 2012-01-02
EP18199105.0A EP3473267B1 (en) 2011-05-24 2012-05-23 Individualized vaccines for cancer

Publications (1)

Publication Number Publication Date
SMT202100611T1 true SMT202100611T1 (it) 2022-01-10

Family

ID=46148823

Family Applications (3)

Application Number Title Priority Date Filing Date
SM20210611T SMT202100611T1 (it) 2011-05-24 2012-05-23 Vaccini individualizzati per il cancro
SM20250304T SMT202500304T1 (it) 2011-05-24 2012-05-23 Vaccini individualizzati per il cancro
SM20230161T SMT202300161T1 (it) 2011-05-24 2012-05-23 Vaccini individualizzati per il cancro

Family Applications After (2)

Application Number Title Priority Date Filing Date
SM20250304T SMT202500304T1 (it) 2011-05-24 2012-05-23 Vaccini individualizzati per il cancro
SM20230161T SMT202300161T1 (it) 2011-05-24 2012-05-23 Vaccini individualizzati per il cancro

Country Status (23)

Country Link
US (3) US10738355B2 (cg-RX-API-DMAC7.html)
JP (6) JP6444171B2 (cg-RX-API-DMAC7.html)
CN (3) CN111286537A (cg-RX-API-DMAC7.html)
AU (4) AU2012261237B2 (cg-RX-API-DMAC7.html)
BR (1) BR112013029834A8 (cg-RX-API-DMAC7.html)
CA (1) CA2836494C (cg-RX-API-DMAC7.html)
DK (3) DK4223311T3 (cg-RX-API-DMAC7.html)
ES (4) ES2746233T3 (cg-RX-API-DMAC7.html)
FI (2) FI4223311T3 (cg-RX-API-DMAC7.html)
HR (3) HRP20250981T1 (cg-RX-API-DMAC7.html)
HU (3) HUE062102T2 (cg-RX-API-DMAC7.html)
LT (4) LT3473267T (cg-RX-API-DMAC7.html)
MX (3) MX386793B (cg-RX-API-DMAC7.html)
NZ (2) NZ730355A (cg-RX-API-DMAC7.html)
PL (2) PL3892295T3 (cg-RX-API-DMAC7.html)
PT (4) PT4223311T (cg-RX-API-DMAC7.html)
RS (3) RS62497B1 (cg-RX-API-DMAC7.html)
RU (1) RU2670745C9 (cg-RX-API-DMAC7.html)
SG (2) SG193553A1 (cg-RX-API-DMAC7.html)
SI (3) SI4223311T1 (cg-RX-API-DMAC7.html)
SM (3) SMT202100611T1 (cg-RX-API-DMAC7.html)
WO (1) WO2012159754A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA201306944B (cg-RX-API-DMAC7.html)

Families Citing this family (235)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9528160B2 (en) 2008-11-07 2016-12-27 Adaptive Biotechnolgies Corp. Rare clonotypes and uses thereof
GB2483810B (en) 2008-11-07 2012-09-05 Sequenta Inc Methods for correlating clonotypes with diseases in a population
US9365901B2 (en) 2008-11-07 2016-06-14 Adaptive Biotechnologies Corp. Monitoring immunoglobulin heavy chain evolution in B-cell acute lymphoblastic leukemia
US9506119B2 (en) 2008-11-07 2016-11-29 Adaptive Biotechnologies Corp. Method of sequence determination using sequence tags
US8748103B2 (en) 2008-11-07 2014-06-10 Sequenta, Inc. Monitoring health and disease status using clonotype profiles
US8628927B2 (en) 2008-11-07 2014-01-14 Sequenta, Inc. Monitoring health and disease status using clonotype profiles
EP2387627B1 (en) 2009-01-15 2016-03-30 Adaptive Biotechnologies Corporation Adaptive immunity profiling and methods for generation of monoclonal antibodies
US20100330571A1 (en) 2009-06-25 2010-12-30 Robins Harlan S Method of measuring adaptive immunity
US8835358B2 (en) 2009-12-15 2014-09-16 Cellular Research, Inc. Digital counting of individual molecules by stochastic attachment of diverse labels
WO2012019168A2 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
ES3005233T3 (en) 2010-10-01 2025-03-14 Modernatx Inc Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
DE12722942T1 (de) 2011-03-31 2021-09-30 Modernatx, Inc. Freisetzung und formulierung von manipulierten nukleinsäuren
LT3473267T (lt) 2011-05-24 2021-11-25 BioNTech SE Individualizuotos vakcinos nuo vėžio
US10385475B2 (en) 2011-09-12 2019-08-20 Adaptive Biotechnologies Corp. Random array sequencing of low-complexity libraries
AU2012325791B2 (en) 2011-10-21 2018-04-05 Adaptive Biotechnologies Corporation Quantification of adaptive immune cell genomes in a complex mixture of cells
EP3904536B1 (en) 2011-12-09 2025-10-29 Adaptive Biotechnologies Corporation Diagnosis of lymphoid malignancies and minimal residual disease detection
US9499865B2 (en) 2011-12-13 2016-11-22 Adaptive Biotechnologies Corp. Detection and measurement of tissue-infiltrating lymphocytes
AU2012352180A1 (en) 2011-12-16 2014-07-31 Moderna Therapeutics, Inc. Modified nucleoside, nucleotide, and nucleic acid compositions
US10941396B2 (en) 2012-02-27 2021-03-09 Becton, Dickinson And Company Compositions and kits for molecular counting
EP2823060B1 (en) 2012-03-05 2018-02-14 Adaptive Biotechnologies Corporation Determining paired immune receptor chains from frequency matched subunits
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
WO2013151663A1 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of membrane proteins
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
BR112014027309A2 (pt) 2012-05-08 2017-07-11 Adaptive Biotechnologies Corp composições e métodos para medir e calibrar a tendên-cia de amplificação em reações de pcr multiplexadas
MX364370B (es) * 2012-07-12 2019-04-24 Persimmune Inc Vacunas contra el cancer personalizadas y terapias de celulas inmunes adoptivas.
EP2885419A4 (en) 2012-08-14 2016-05-25 Moderna Therapeutics Inc ENZYMES AND POLYMERASES FOR RNA SYNTHESIS
US10501801B2 (en) 2012-09-28 2019-12-10 University Of Connecticut Identification of tumor-protective epitopes for the treatment of cancers
CN105189779B (zh) 2012-10-01 2018-05-11 适应生物技术公司 通过适应性免疫受体多样性和克隆性表征进行的免疫能力评估
HRP20220607T1 (hr) 2012-11-26 2022-06-24 Modernatx, Inc. Terminalno modificirana rna
US10155031B2 (en) * 2012-11-28 2018-12-18 Biontech Rna Pharmaceuticals Gmbh Individualized vaccines for cancer
WO2014093186A1 (en) * 2012-12-12 2014-06-19 Garvin Alex M Non-invasive detection of colorectal neoplasia using circular consensus sequencing
WO2014113204A1 (en) 2013-01-17 2014-07-24 Personalis, Inc. Methods and systems for genetic analysis
EP2968391A1 (en) 2013-03-13 2016-01-20 Moderna Therapeutics, Inc. Long-lived polynucleotide molecules
EP2971010B1 (en) 2013-03-14 2020-06-10 ModernaTX, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
CA2906218A1 (en) * 2013-03-15 2014-09-18 Adaptive Biotechnologies Corporation Uniquely tagged rearranged adaptive immune receptor genes in a complex gene set
CN118750591A (zh) * 2013-04-07 2024-10-11 博德研究所 用于个性化瘤形成疫苗的组合物和方法
WO2014180490A1 (en) * 2013-05-10 2014-11-13 Biontech Ag Predicting immunogenicity of t cell epitopes
US9708657B2 (en) 2013-07-01 2017-07-18 Adaptive Biotechnologies Corp. Method for generating clonotype profiles using sequence tags
US20160186260A1 (en) * 2013-07-26 2016-06-30 Sequenta, Llc Cancer vaccination with antigen evolution
EP3039158B1 (en) 2013-08-28 2018-11-14 Cellular Research, Inc. Massively parallel single cell analysis
GB2534067B (en) 2013-08-30 2021-07-21 Personalis Inc Methods and systems for genomic analysis
EP3052106A4 (en) 2013-09-30 2017-07-19 ModernaTX, Inc. Polynucleotides encoding immune modulating polypeptides
WO2015051275A1 (en) 2013-10-03 2015-04-09 Personalis, Inc. Methods for analyzing genotypes
EP3055676A1 (en) 2013-10-07 2016-08-17 Cellular Research, Inc. Methods and systems for digitally counting features on arrays
WO2015077717A1 (en) 2013-11-25 2015-05-28 The Broad Institute Inc. Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
DK3077539T3 (en) * 2013-12-02 2018-11-19 Personal Genome Diagnostics Inc Procedure for evaluating minority variations in a sample
WO2015085147A1 (en) 2013-12-05 2015-06-11 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
EP3076992B1 (en) * 2013-12-06 2022-04-06 The Broad Institute, Inc. Formulations for neoplasia vaccines
CA2934073A1 (en) * 2013-12-20 2015-06-25 The Broad Institute, Inc. Combination therapy with neoantigen vaccine
ES2741740T3 (es) 2014-03-05 2020-02-12 Adaptive Biotechnologies Corp Métodos que usan moléculas sintéticas que contienen segmentos de nucleótidos aleatorios
US10066265B2 (en) 2014-04-01 2018-09-04 Adaptive Biotechnologies Corp. Determining antigen-specific t-cells
ES2777529T3 (es) 2014-04-17 2020-08-05 Adaptive Biotechnologies Corp Cuantificación de genomas de células inmunitarias adaptativas en una mezcla compleja de células
ES3009962T3 (en) 2014-04-23 2025-03-31 Modernatx Inc Nucleic acid vaccines
US10017759B2 (en) * 2014-06-26 2018-07-10 Illumina, Inc. Library preparation of tagged nucleic acid
US10564165B2 (en) 2014-09-10 2020-02-18 Genentech, Inc. Identification of immunogenic mutant peptides using genomic, transcriptomic and proteomic information
US11338026B2 (en) 2014-09-10 2022-05-24 The University Of Connecticut Identification of immunologically protective neo-epitopes for the treatment of cancers
CA2963364A1 (en) 2014-10-02 2016-04-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of isolating t cells having antigenic specificity for a cancer-specific mutation
US10392663B2 (en) 2014-10-29 2019-08-27 Adaptive Biotechnologies Corp. Highly-multiplexed simultaneous detection of nucleic acids encoding paired adaptive immune receptor heterodimers from a large number of samples
EP3212808B1 (en) 2014-10-30 2022-03-02 Personalis, Inc. Methods for using mosaicism in nucleic acids sampled distal to their origin
US10246701B2 (en) 2014-11-14 2019-04-02 Adaptive Biotechnologies Corp. Multiplexed digital quantitation of rearranged lymphoid receptors in a complex mixture
AU2015353581A1 (en) 2014-11-25 2017-06-15 Adaptive Biotechnologies Corporation Characterization of adaptive immune response to vaccination or infection using immune repertoire sequencing
ES3049406T3 (en) 2014-12-19 2025-12-16 Broad Inst Inc Methods for profiling the t-cell-receptor repertoire
EP3234193B1 (en) 2014-12-19 2020-07-15 Massachusetts Institute of Technology Molecular biomarkers for cancer immunotherapy
WO2016128060A1 (en) * 2015-02-12 2016-08-18 Biontech Ag Predicting t cell epitopes useful for vaccination
WO2016134078A1 (en) * 2015-02-19 2016-08-25 Becton, Dickinson And Company High-throughput single-cell analysis combining proteomic and genomic information
ES2858306T3 (es) 2015-02-24 2021-09-30 Adaptive Biotechnologies Corp Método para determinar el estado de HLA mediante secuenciación del repertorio inmunitario
EP3261605B2 (en) 2015-02-26 2022-04-20 SiO2 Medical Products, Inc. Cycloolefin polymer container with a scratch resistant and anti-static coating
US9727810B2 (en) 2015-02-27 2017-08-08 Cellular Research, Inc. Spatially addressable molecular barcoding
JP7508191B2 (ja) 2015-03-30 2024-07-01 ベクトン・ディキンソン・アンド・カンパニー コンビナトリアルバーコーディングのための方法および組成物
AU2016242967B2 (en) 2015-04-01 2021-07-01 Adaptive Biotechnologies Corp. Method of identifying human compatible T cell receptors specific for an antigenic target
WO2016172373A1 (en) 2015-04-23 2016-10-27 Cellular Research, Inc. Methods and compositions for whole transcriptome amplification
CN107750278B (zh) * 2015-04-27 2023-10-03 癌症研究技术有限公司 治疗癌症的方法
WO2016180467A1 (en) 2015-05-11 2016-11-17 Biontech Cell & Gene Therapies Gmbh Enhancing the effect of car-engineered t cells by means of nucleic acid vaccination
MX392028B (es) * 2015-05-13 2025-03-04 Agenus Inc Vacunas para el tratamiento y prevención del cáncer.
PE20180670A1 (es) 2015-05-20 2018-04-19 Broad Inst Inc Neoantigenos compartidos
WO2016196229A1 (en) 2015-06-01 2016-12-08 Cellular Research, Inc. Methods for rna quantification
TW202241500A (zh) * 2015-06-09 2022-11-01 美商博德研究所有限公司 用於贅瘤疫苗之調配物及其製備方法
MA42543A (fr) * 2015-07-30 2018-06-06 Modernatx Inc Arn épitope peptidiques concatémériques
GB201516047D0 (en) 2015-09-10 2015-10-28 Cancer Rec Tech Ltd Method
KR102395450B1 (ko) 2015-09-11 2022-05-09 셀룰러 리서치, 인크. 핵산 라이브러리 정규화를 위한 방법 및 조성물
US10849920B2 (en) 2015-10-05 2020-12-01 Modernatx, Inc. Methods for therapeutic administration of messenger ribonucleic acid drugs
KR20250161050A (ko) * 2015-10-12 2025-11-14 난토믹스, 엘엘씨 바이러스성 암 네오에피토프를 위한 조성물 및 방법
MX387275B (es) * 2015-10-12 2025-03-18 Nantomics Llc Neoepítopos virales y sus usos
JP2018532777A (ja) * 2015-10-22 2018-11-08 モデルナティーエックス， インコーポレイテッド 癌ワクチン
EP3389630B1 (en) 2015-12-16 2023-11-08 Gritstone bio, Inc. Neoantigen identification, manufacture, and use
CN105349533A (zh) * 2015-12-21 2016-02-24 生工生物工程（上海）股份有限公司 构建链特异性转录组文库的方法
WO2017118702A1 (en) * 2016-01-08 2017-07-13 Vaccibody As Neoepitope rna cancer vaccine
CA3008437A1 (en) * 2016-01-08 2017-07-13 Vaccibody As Therapeutic anticancer neoepitope vaccine
US11154597B2 (en) 2016-03-24 2021-10-26 Nantcell, Inc. Sequence arrangements and sequences for neoepitope presentation
SG11201808196UA (en) 2016-03-31 2018-10-30 Neon Therapeutics Inc Neoantigens and methods of their use
EP3446119A1 (en) 2016-04-18 2019-02-27 The Broad Institute Inc. Improved hla epitope prediction
EP3445392A1 (en) * 2016-04-22 2019-02-27 CureVac AG Rna encoding a tumor antigen
EP3452614B1 (en) 2016-05-02 2023-06-28 Becton, Dickinson and Company Accurate molecular barcoding
CA3022924A1 (en) * 2016-05-04 2017-11-09 Immunovaccine Technologies Inc. Vaccine compositions comprising an amphipathic compound, a neoantigen and a hydrophobic carrier, and methods of use thereof
WO2017194170A1 (en) 2016-05-13 2017-11-16 Biontech Rna Pharmaceuticals Gmbh Methods for predicting the usefulness of proteins or protein fragments for immunotherapy
US10301677B2 (en) 2016-05-25 2019-05-28 Cellular Research, Inc. Normalization of nucleic acid libraries
EP3465502B1 (en) 2016-05-26 2024-04-10 Becton, Dickinson and Company Molecular label counting adjustment methods
KR20200138418A (ko) * 2016-05-27 2020-12-09 이투빅스 코포레이션 네오에피토프 백신 조성물 및 이의 사용 방법
US11299783B2 (en) 2016-05-27 2022-04-12 Personalis, Inc. Methods and systems for genetic analysis
US10202641B2 (en) 2016-05-31 2019-02-12 Cellular Research, Inc. Error correction in amplification of samples
US10640763B2 (en) 2016-05-31 2020-05-05 Cellular Research, Inc. Molecular indexing of internal sequences
SG11201811258UA (en) * 2016-07-13 2019-01-30 Vaximm Ag Process for the production of a dna vaccine for cancer immunotherapy
LT3488443T (lt) * 2016-07-20 2021-10-25 BioNTech SE Neoepitopų, kaip ligai specifinių taikinių, parinkimas padidinto efektyvumo terapijai
US10428325B1 (en) 2016-09-21 2019-10-01 Adaptive Biotechnologies Corporation Identification of antigen-specific B cell receptors
EP3516400B1 (en) 2016-09-26 2023-08-16 Becton, Dickinson and Company Measurement of protein expression using reagents with barcoded oligonucleotide sequences
KR102790039B1 (ko) 2016-11-08 2025-04-04 벡톤 디킨슨 앤드 컴퍼니 세포 표지 분류 방법
ES2980967T3 (es) 2016-11-08 2024-10-03 Becton Dickinson Co Métodos para la clasificación de perfiles de expresión
US20190321481A1 (en) 2016-11-11 2019-10-24 Nantbio, Inc. Immunomodulatory compositions, processes for making the same, and methods for inhibiting cytokine storms
CN108090325B (zh) * 2016-11-23 2022-01-25 中国科学院昆明动物研究所 一种应用β-稳定性分析单细胞测序数据的方法
WO2018132753A1 (en) * 2017-01-13 2018-07-19 Nantbio, Inc. Validation of neoepitope-based treatment
JP7104048B2 (ja) 2017-01-13 2022-07-20 セルラー リサーチ， インコーポレイテッド 流体チャネルの親水性コーティング
US12331359B2 (en) * 2017-01-18 2025-06-17 Michael Laessig Neoantigens and uses thereof for treating cancer
EP3574116A1 (en) 2017-01-24 2019-12-04 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
EP3576780A1 (en) 2017-02-01 2019-12-11 Modernatx, Inc. Immunomodulatory therapeutic mrna compositions encoding activating oncogene mutation peptides
KR20190120233A (ko) * 2017-02-01 2019-10-23 모더나티엑스, 인크. Rna 암 백신
US11319583B2 (en) 2017-02-01 2022-05-03 Becton, Dickinson And Company Selective amplification using blocking oligonucleotides
FI3580561T3 (fi) 2017-02-12 2023-12-12 Biontech Us Inc Hla-pohjaiset menetelmät ja koostumukset sekä niiden käyttö
CA3057505A1 (en) 2017-03-31 2018-10-04 The Board Of Trustees Of The Leland Stanford Junior University Methods of treating t cell exhaustion by inhibiting or modulating t cell receptor signaling
CN118370809A (zh) 2017-04-03 2024-07-23 百欧恩泰美国公司 蛋白质抗原及其用途
MA48047A (fr) 2017-04-05 2020-02-12 Modernatx Inc Réduction ou élimination de réponses immunitaires à des protéines thérapeutiques administrées par voie non intraveineuse, par exemple par voie sous-cutanée
SG11201909882SA (en) 2017-04-24 2019-11-28 Nantcell Inc Targeted neoepitope vectors and methods therefor
TW201907937A (zh) 2017-05-08 2019-03-01 美商葛利史東腫瘤科技公司 阿爾法病毒新抗原載體
CA3062883C (en) 2017-05-11 2024-04-02 Theralase Biotech, Inc. Vaccine containing cancer cells inactivated by photodynamic treatment with metal-based coordination complexes, and immunotherapy method using same
EP3933408A1 (en) 2017-05-30 2022-01-05 Nant Holdings IP LLC Circulating tumor cell enrichment using neoepitopes
JP7536450B2 (ja) 2017-06-05 2024-08-20 ベクトン・ディキンソン・アンド・カンパニー 単一細胞用のサンプルインデックス付加
WO2018224166A1 (en) * 2017-06-09 2018-12-13 Biontech Rna Pharmaceuticals Gmbh Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy
JP7334124B2 (ja) 2017-06-21 2023-08-28 トランジェーヌ 個別化ワクチン
US20200219586A1 (en) 2017-06-27 2020-07-09 Institute For Cancer Research D/B/A The Research Institute Of Fox Chase Cancer Center MHC-1 Genotypes Restricts The Oncogenic Mutational Landscape
IL271965B2 (en) * 2017-07-12 2023-03-01 Nouscom Ag Preparations containing a neoantigenic vaccine for the treatment of cancer
US10636512B2 (en) 2017-07-14 2020-04-28 Cofactor Genomics, Inc. Immuno-oncology applications using next generation sequencing
US12504380B2 (en) 2017-09-25 2025-12-23 University Of Florida Research Foundation, Incorporated Immunoassays for detection of ran proteins
JP7227237B2 (ja) 2017-10-10 2023-02-21 グリットストーン バイオ インコーポレイテッド ホットスポットを利用した新生抗原の特定
CN111630602A (zh) * 2017-11-22 2020-09-04 磨石肿瘤生物技术公司 减少新抗原的接合表位呈递
US20200354730A1 (en) * 2017-11-27 2020-11-12 Nantcell, Inc. Improved Yeast Polytope Vaccine Compositions And Methods
US11254980B1 (en) 2017-11-29 2022-02-22 Adaptive Biotechnologies Corporation Methods of profiling targeted polynucleotides while mitigating sequencing depth requirements
WO2019105485A1 (zh) * 2017-12-01 2019-06-06 上海桀蒙生物技术有限公司 个性化癌症疫苗的制备方法
WO2019126186A1 (en) 2017-12-18 2019-06-27 Neon Therapeutics, Inc. Neoantigens and uses thereof
WO2019125864A1 (en) 2017-12-18 2019-06-27 Personal Genome Diagnostics Inc. Machine learning system and method for somatic mutation discovery
CN111492068B (zh) 2017-12-19 2025-03-21 贝克顿迪金森公司 与寡核苷酸相关联的颗粒
AU2019205330B2 (en) 2018-01-04 2025-09-11 Iconic Therapeutics Llc Anti-tissue factor antibodies, antibody-drug conjugates, and related methods
US20210005285A1 (en) * 2018-03-14 2021-01-07 Koninklijke Philips N.V. System and method using local unique features to interpret transcript expression levels for rna sequencing data
AU2019244115A1 (en) * 2018-03-30 2020-11-19 Juno Diagnostics, Inc. Deep learning-based methods, devices, and systems for prenatal testing
CA3096909A1 (en) 2018-04-26 2019-10-31 Agenus Inc. Heat shock protein-binding peptide compositions and methods of use thereof
CN112272710A (zh) 2018-05-03 2021-01-26 贝克顿迪金森公司 高通量多组学样品分析
CN118910215A (zh) 2018-05-03 2024-11-08 贝克顿迪金森公司 在相对的转录物末端进行分子条形码化
IL259392A (en) 2018-05-15 2018-08-01 Yeda Res & Dev Vaccination with cancer neoantigens
WO2019227106A1 (en) * 2018-05-25 2019-11-28 The Wistar Institute Tumor-specific neoantigens and methods of using the same
CN108897986B (zh) * 2018-05-29 2020-11-27 中南大学 一种基于蛋白质信息的基因组序列拼接方法
US10801064B2 (en) 2018-05-31 2020-10-13 Personalis, Inc. Compositions, methods and systems for processing or analyzing multi-species nucleic acid samples
US11814750B2 (en) 2018-05-31 2023-11-14 Personalis, Inc. Compositions, methods and systems for processing or analyzing multi-species nucleic acid samples
JP7534962B2 (ja) 2018-06-19 2024-08-15 ビオンテック ユーエス インコーポレイテッド ネオ抗原およびその使用
KR20210038886A (ko) * 2018-06-27 2021-04-08 모더나티엑스, 인크. 개인화된 암 백신 에피토프 선택
WO2020020444A1 (en) * 2018-07-24 2020-01-30 Biontech Rna Pharmaceuticals Gmbh Individualized vaccines for cancer
WO2020022897A1 (en) 2018-07-26 2020-01-30 Frame Pharmaceuticals B.V. Method of preparing subject-specific immunogenic compositions based on a neo open-reading-frame peptide database
MX2021003654A (es) 2018-09-27 2021-05-28 Nykode Therapeutics AS Metodo para seleccionar neoepitopes.
US11639517B2 (en) 2018-10-01 2023-05-02 Becton, Dickinson And Company Determining 5′ transcript sequences
US20210382068A1 (en) 2018-10-02 2021-12-09 Dana-Farber Cancer Institute, Inc. Hla single allele lines
CN114573688A (zh) * 2018-10-19 2022-06-03 杭州纽安津生物科技有限公司 通用性多肽疫苗及其在制备治疗/预防胰腺癌药物中的应用
CA3118947A1 (en) * 2018-11-07 2020-05-14 Modernatx, Inc. Rna cancer vaccines
US11932849B2 (en) 2018-11-08 2024-03-19 Becton, Dickinson And Company Whole transcriptome analysis of single cells using random priming
AU2019379306B2 (en) * 2018-11-15 2025-03-06 Nouscom Ag Selection of cancer mutations for generation of a personalized cancer vaccine
CN113195717A (zh) 2018-12-13 2021-07-30 贝克顿迪金森公司 单细胞全转录组分析中的选择性延伸
WO2020131586A2 (en) 2018-12-17 2020-06-25 The Broad Institute, Inc. Methods for identifying neoantigens
CN113474840B (zh) * 2018-12-21 2024-12-17 百欧恩泰美国公司 用于预测hla ii类特异性表位及表征cd4+ t细胞的方法和系统
GB201821207D0 (en) 2018-12-24 2019-02-06 Tcer Ab Immunotherapy therapy
GB201821205D0 (en) * 2018-12-24 2019-02-06 Tcer Ab Immunotherapy
US20220093217A1 (en) * 2019-01-08 2022-03-24 Caris Mpi, Inc. Genomic profiling similarity
AU2020208193A1 (en) * 2019-01-14 2021-07-29 BioNTech SE Methods of treating cancer with a PD-1 axis binding antagonist and an RNA vaccine
WO2020150356A1 (en) 2019-01-16 2020-07-23 Becton, Dickinson And Company Polymerase chain reaction normalization through primer titration
EP4242322B1 (en) 2019-01-23 2024-08-21 Becton, Dickinson and Company Oligonucleotides associated with antibodies
EP3921443A1 (en) 2019-02-08 2021-12-15 F. Hoffmann-La Roche AG Diagnostic and therapeutic methods for cancer
US12071617B2 (en) 2019-02-14 2024-08-27 Becton, Dickinson And Company Hybrid targeted and whole transcriptome amplification
WO2020167240A1 (en) * 2019-02-15 2020-08-20 Rjan Holdng Ab Autologous cancer tumour associated extrachromosomal circular dna for use as a therapeutic vaccine
AU2020232971A1 (en) * 2019-03-01 2021-09-23 Scott R. BURKHOLZ Design, manufacture, and use of personalized cancer vaccines
WO2020184551A1 (ja) 2019-03-13 2020-09-17 東洋紡株式会社 核酸の生成および増幅
WO2020214642A1 (en) 2019-04-19 2020-10-22 Becton, Dickinson And Company Methods of associating phenotypical data and single cell sequencing data
CN112011833B (zh) * 2019-05-30 2024-04-26 上海桀蒙生物技术有限公司 筛选和分离肿瘤新生抗原的方法
IL288283B2 (en) 2019-05-30 2025-05-01 Gritstone Bio Inc Modified adenovirus
US11939622B2 (en) 2019-07-22 2024-03-26 Becton, Dickinson And Company Single cell chromatin immunoprecipitation sequencing assay
CN110277135B (zh) * 2019-08-10 2021-06-01 杭州新范式生物医药科技有限公司 一种基于预期疗效选择个体化肿瘤新抗原的方法和系统
EP4031562A4 (en) * 2019-09-20 2023-11-01 University of Florida Research Foundation, Incorporated DETECTION OF ANTIBODIES AGAINST RAN PROTEINS FROM SERUM AND TISSUE LYSATES
WO2021055973A2 (en) * 2019-09-20 2021-03-25 Navi Bio-Therapeutics, Inc. Personalized cancer immunotherapy
US12394502B2 (en) 2019-10-02 2025-08-19 The General Hospital Corporation Method for predicting HLA-binding peptides using protein structural features
EP4055610A4 (en) 2019-11-05 2023-11-29 Personalis, Inc. ESTIMATION OF TUMOR PURITY FROM SINGLE SAMPLES
JP7522189B2 (ja) 2019-11-08 2024-07-24 ベクトン・ディキンソン・アンド・カンパニー 免疫レパートリーシーケンシングのための完全長ｖ（ｄ）ｊ情報を得るためのランダムプライミングの使用
CN112795647B (zh) * 2019-11-14 2022-08-16 北京肿瘤医院(北京大学肿瘤医院) 一种肿瘤标志物及其应用
AR120741A1 (es) 2019-12-13 2022-03-16 Genentech Inc Anticuerpos anti-ly6g6d y métodos de uso
WO2021146207A1 (en) 2020-01-13 2021-07-22 Becton, Dickinson And Company Methods and compositions for quantitation of proteins and rna
ES2993319T3 (en) 2020-01-29 2024-12-27 Becton Dickinson Co Barcoded wells for spatial mapping of single cells through sequencing
CN115151810A (zh) 2020-02-25 2022-10-04 贝克顿迪金森公司 实现使用单细胞样品作为单色补偿对照的双特异性探针
WO2021184017A1 (en) 2020-03-13 2021-09-16 Codiak Biosciences, Inc. Extracellular vesicles for treating neurological disorders
JP2023518414A (ja) 2020-03-20 2023-05-01 コディアック バイオサイエンシーズ， インコーポレイテッド 治療のための細胞外小胞
US11920202B2 (en) 2020-04-09 2024-03-05 University Of Connecticut Unbiased identification of tumor rejection mediating neoepitopes
CN115605614A (zh) 2020-05-14 2023-01-13 贝克顿迪金森公司（Us） 用于免疫组库谱分析的引物
CA3185387A1 (en) 2020-05-26 2021-12-02 Dionis Therapeutics, Inc. Nucleic acid artificial mini-proteome libraries
CN115803445A (zh) 2020-06-02 2023-03-14 贝克顿迪金森公司 用于5撇基因表达测定的寡核苷酸和珠
US11932901B2 (en) 2020-07-13 2024-03-19 Becton, Dickinson And Company Target enrichment using nucleic acid probes for scRNAseq
WO2022026909A1 (en) 2020-07-31 2022-02-03 Becton, Dickinson And Company Single cell assay for transposase-accessible chromatin
IL300026A (en) 2020-08-06 2023-03-01 Gritstone Bio Inc Multiepitope vaccine cassettes
EP4196612A1 (en) 2020-08-12 2023-06-21 Genentech, Inc. Diagnostic and therapeutic methods for cancer
JP2023539332A (ja) * 2020-08-31 2023-09-13 ワールド バイオテック リジェネラティブ メディカル グループ リミテッド 個別化された免疫原性組成物及びその製造方法及びその使用
EP4216993A2 (en) 2020-09-23 2023-08-02 Codiak BioSciences, Inc. Methods of producing extracellular vesicles
WO2022109343A1 (en) 2020-11-20 2022-05-27 Becton, Dickinson And Company Profiling of highly expressed and lowly expressed proteins
US11161892B1 (en) 2020-12-07 2021-11-02 Think Therapeutics, Inc. Method of compact peptide vaccines using residue optimization
US11421015B2 (en) 2020-12-07 2022-08-23 Think Therapeutics, Inc. Method of compact peptide vaccines using residue optimization
CN116710115A (zh) 2020-11-20 2023-09-05 思维疗法股份有限公司 用于优化的肽疫苗的组合物和方法
US11058751B1 (en) 2020-11-20 2021-07-13 Think Therapeutics, Inc. Compositions for optimized RAS peptide vaccines
CN117083081A (zh) 2020-12-14 2023-11-17 百欧恩泰美国公司 用于癌症免疫疗法的组织特异性抗原
US12392771B2 (en) 2020-12-15 2025-08-19 Becton, Dickinson And Company Single cell secretome analysis
US11464842B1 (en) 2021-04-28 2022-10-11 Think Therapeutics, Inc. Compositions and method for optimized peptide vaccines using residue optimization
CN117999355A (zh) 2021-08-24 2024-05-07 生物技术欧洲股份公司 体外转录技术
US12297508B2 (en) 2021-10-05 2025-05-13 Personalis, Inc. Customized assays for personalized cancer monitoring
WO2023076733A1 (en) 2021-11-01 2023-05-04 Dana-Farber Cancer Institute, Inc. Biologically selected nucleic acid artificial mini-proteome libraries
EP4431603A4 (en) 2021-11-10 2025-10-29 Toyo Boseki IMPROVED BANK PREPARATION METHOD
CN114181287B (zh) * 2021-12-10 2023-09-19 商丘美兰生物工程有限公司 一种dna病毒疫苗的制备方法
CN114410778B (zh) * 2021-12-29 2024-03-19 中南大学湘雅医院 Pf543在制备pd-l1/pd-1单抗肿瘤免疫治疗药物中的应用
CN114350800B (zh) * 2021-12-29 2024-03-19 中南大学湘雅医院 Sphk1在制备pd-l1/pd-1单抗肿瘤免疫治疗药物中的应用
KR20230130804A (ko) * 2022-03-04 2023-09-12 (주)큐리진 순환종양세포 검출을 위한 아데노바이러스 5/3 형
EP4253550A1 (en) 2022-04-01 2023-10-04 GenCC GmbH 6 Co. KG Method for the manufacture of a viral system, a vector system or any transport system for cancer-specific crispr complexes
WO2023209068A1 (en) 2022-04-28 2023-11-02 Carbocalyx Gmbh Personalized anticancer vaccine comprising glycoengineered tumour cells or tumour cell fragments
WO2024015892A1 (en) 2022-07-13 2024-01-18 The Broad Institute, Inc. Hla-ii immunopeptidome methods and systems for antigen discovery
IL319414A (en) * 2022-09-23 2025-05-01 BioNTech SE Compositions for delivering antigens at the liver level and related methods
WO2024063788A1 (en) * 2022-09-23 2024-03-28 BioNTech SE Compositions for delivery of malaria antigens and related methods
WO2024083345A1 (en) 2022-10-21 2024-04-25 BioNTech SE Methods and uses associated with liquid compositions
EP4656735A1 (en) 2023-01-26 2025-12-03 Toyobo Co., Ltd. Inibhition of reverse transcription derived from ribosomal rna
WO2025024337A1 (en) * 2023-07-24 2025-01-30 BioNTech SE Compositions for delivery of plasmodium antigens and related methods
WO2025064850A1 (en) * 2023-09-22 2025-03-27 BioNTech SE Rna constructs with n-terminal degrons to enhance an immune response
WO2025097055A2 (en) 2023-11-02 2025-05-08 The Broad Institute, Inc. Compositions and methods of use of t cells in immunotherapy
WO2025146078A1 (en) * 2024-01-04 2025-07-10 Everest Medicines (China) Co., Ltd. Cancer vaccines and uses thereof
US20250335785A1 (en) 2024-03-11 2025-10-30 Instadeep Ltd Systems and methods for machine learning-based genome annotation
WO2025202937A1 (en) 2024-03-26 2025-10-02 BioNTech SE Cancer vaccines
WO2025207807A1 (en) * 2024-03-27 2025-10-02 The University Of Florida Research Foundation, Inc. Ctc rna-loaded nanoparticles and use thereof for the treatment of cancer
WO2025257735A1 (en) 2024-06-10 2025-12-18 BioNTech SE Systems and methods for machine learning model-based prediction of immune response
CN119049567B (zh) * 2024-08-08 2025-07-22 笙源生命科技(安吉)有限公司 一种基于单细胞测序区分嵌合体动物模型中异种杂交样本遗传物质和细胞物种来源的方法

Family Cites Families (122)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5804381A (en) 1996-10-03 1998-09-08 Cornell Research Foundation Isolated nucleic acid molecule encoding an esophageal cancer associated antigen, the antigen itself, and uses thereof
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US6235525B1 (en) 1991-05-23 2001-05-22 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-3 and uses thereof
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US7422902B1 (en) 1995-06-07 2008-09-09 The University Of British Columbia Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
WO1997024447A1 (en) 1996-01-02 1997-07-10 Chiron Corporation Immunostimulation mediated by gene-modified dendritic cells
DE69714033T2 (de) * 1996-04-19 2003-02-13 The Government Of The United States Of America, As Represented By The Secretary National Institute Of Health Mutierte ras peptide zur zeugung von cd8+ zytitoxischen t lymphoizyten
JP4108126B2 (ja) 1996-04-26 2008-06-25 リュクスウニヴェルシテート テ レイデン Ｔ細胞ペプチド・エピトープの選択と産生方法および選択したエピトープを組込むワクチン
KR100507660B1 (ko) 1996-09-13 2005-08-10 리폭센 테크놀로지즈 리미티드 리포좀
ATE229810T1 (de) * 1996-10-11 2003-01-15 Univ California Krebs immuntherapie unter verwendung von tumorzellen kombiniert mit lymphozytmischungen
EP0839912A1 (en) 1996-10-30 1998-05-06 Instituut Voor Dierhouderij En Diergezondheid (Id-Dlo) Infectious clones of RNA viruses and vaccines and diagnostic assays derived thereof
US6074645A (en) 1996-11-12 2000-06-13 City Of Hope Immuno-reactive peptide CTL epitopes of human cytomegalovirus
KR20010024585A (ko) 1997-11-06 2001-03-26 로셰 디아그노스틱스 게엠베하 종양-특이적 항원, 이들의 제조방법, 및 이들의 면역화 및진단에서의 용도
WO1999034014A2 (en) 1997-12-23 1999-07-08 Roche Diagnostics Gmbh A method for the determination of a nucleic acid
AU1774299A (en) * 1997-12-24 1999-07-19 Imperial Cancer Research Technology Limited Polymorphisms within the rsk-3 gene related to cancer and methods of diagnosis, prognosis, and treatment
US6432925B1 (en) 1998-04-16 2002-08-13 John Wayne Cancer Institute RNA cancer vaccine and methods for its use
JP2002526421A (ja) 1998-10-05 2002-08-20 ジェンザイム・コーポレーション 癌細胞に差別的に発現する癌ワクチン設計のための遺伝子
AU4700100A (en) 1999-05-06 2000-11-21 Wake Forest University Compositions and methods for identifying antigens which elicit an immune response
DK1214097T3 (da) 1999-09-16 2009-11-16 Eisai Corp North America Nukleinsyrer kodende for polyepitop-polypeptider
EP1222289B1 (en) * 1999-10-20 2008-04-16 The Johns Hopkins University School Of Medicine Chimeric immunogenic compositions and nucleic acids encoding them
JP5640237B2 (ja) 1999-11-30 2014-12-17 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ リミテッド 癌関連抗原をコードする単離された核酸分子、その抗原そのものおよびその使用
DE60035523T2 (de) 1999-12-28 2008-03-20 Pharmexa Inc., San Diego Optimierte minigene und dadurch kodierte peptide
US7462354B2 (en) 1999-12-28 2008-12-09 Pharmexa Inc. Method and system for optimizing minigenes and peptides encoded thereby
CA2412026A1 (en) 2000-06-07 2001-12-13 Biosynexus Incorporated Immunostimulatory rna/dna hybrid molecules
ES2454640T3 (es) 2000-08-03 2014-04-11 Johns Hopkins University Vacuna molecular que lleva unida un polipéptido de chaperona del retículo endoplasmático a un antígeno
US6472176B2 (en) 2000-12-14 2002-10-29 Genvec, Inc. Polynucleotide encoding chimeric protein and related vector, cell, and method of expression thereof
EP1800697B1 (de) 2001-06-05 2010-04-14 CureVac GmbH Stabilisierte mRNA mit erhöhtem G/C-Gehalt für die Gentherapie
AUPR593101A0 (en) * 2001-06-26 2001-07-19 Council Of The Queensland Institute Of Medical Research, The Cytomegalovirus t cell epitopes
WO2003046189A1 (en) 2001-11-26 2003-06-05 The University Of Queensland Flavivirus vaccine delivery system
DE10162480A1 (de) 2001-12-19 2003-08-07 Ingmar Hoerr Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen
AU2003235707A1 (en) 2002-01-18 2003-07-30 Curevac Gmbh Immunogenic preparations and vaccines on the basis of mrna
AUPS054702A0 (en) 2002-02-14 2002-03-07 Immunaid Pty Ltd Cancer therapy
WO2003070162A2 (en) * 2002-02-19 2003-08-28 Genzyme Corporation Par-3 compounds for therapy and diagnosis and methods for using same
US20050222060A1 (en) * 2002-03-15 2005-10-06 Bot Adrian L Compositions and methods to initiate or enhance antibody and major-histocompatibility class I or class II-restricted t cell responses by using immunomodulatory, non-coding rna motifs
DE60328685D1 (de) 2002-06-13 2009-09-17 Merck Patent Gmbh Verfahren für die identifizierung von allo-antigenen und ihren verwendung für krebs therapie und transplantation
DE10229872A1 (de) 2002-07-03 2004-01-29 Curevac Gmbh Immunstimulation durch chemisch modifizierte RNA
DE10335833A1 (de) * 2003-08-05 2005-03-03 Curevac Gmbh Transfektion von Blutzellen mit mRNA zur Immunstimulation und Gentherapie
IL158140A0 (en) 2003-09-25 2004-03-28 Hadasit Med Res Service Multiepitope polypeptides for cancer immunotherapy
DE10344799A1 (de) 2003-09-26 2005-04-14 Ganymed Pharmaceuticals Ag Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
PT2286794T (pt) 2003-10-15 2016-07-13 Syncore Biotechnology Co Ltd Uso de lipossomas catiónicos contendo placlitaxel
DK1692516T3 (da) 2003-10-24 2011-02-28 Immunaid Pty Ltd Terapifremgangsmåde
EP1589030A1 (en) * 2004-04-14 2005-10-26 Friedrich-Alexander-Universität Erlangen-Nürnberg Bob-1 specific T cells and methods to use
US7303881B2 (en) 2004-04-30 2007-12-04 Pds Biotechnology Corporation Antigen delivery compositions and methods of use
DE102004023187A1 (de) 2004-05-11 2005-12-01 Ganymed Pharmaceuticals Ag Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
DE102004035227A1 (de) 2004-07-21 2006-02-16 Curevac Gmbh mRNA-Gemisch zur Vakzinierung gegen Tumorerkrankungen
DE102004057303A1 (de) 2004-11-26 2006-06-01 Merck Patent Gmbh Stabile Kristallmodifikationen von DOTAP Chlorid
AU2005321905A1 (en) 2004-12-29 2006-07-06 Mannkind Corporation Methods to bypass CD+4 cells in the induction of an immune response
EP1896582A4 (en) 2005-05-09 2009-04-08 Ono Pharmaceutical Co HUMAN MONOCLONAL ANTIBODIES AGAINST PROGRAMMED CELL DEATH 1 (PD-1) AND METHOD FOR CREATING TREATMENT WITH ANTI-PD-1 ANTIBODIES ALONE OR IN COMBINATION WITH OTHER IMMUNOTHERAPEUTICS
CN104356236B (zh) 2005-07-01 2020-07-03 E.R.施贵宝&圣斯有限责任公司 抗程序性死亡配体1(pd-l1)的人单克隆抗体
EP4174179B1 (en) 2005-08-23 2025-05-07 The Trustees of the University of Pennsylvania Rna containing modified nucleosides and methods of use thereof
DE102005041616B4 (de) 2005-09-01 2011-03-17 Johannes-Gutenberg-Universität Mainz Melanom-assoziierte MHC Klasse I assoziierte Oligopeptide und für diese kodierende Polynukleotide und deren Verwendungen
EP1762575A1 (en) 2005-09-12 2007-03-14 Ganymed Pharmaceuticals AG Identification of tumor-associated antigens for diagnosis and therapy
DE102005046490A1 (de) 2005-09-28 2007-03-29 Johannes-Gutenberg-Universität Mainz Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
EP1994181A4 (en) 2006-02-27 2010-05-19 Univ Arizona IDENTIFICATION AND USE OF NOVOPEPTIDES FOR THE TREATMENT OF CANCER
MX2008011839A (es) 2006-03-13 2008-11-04 Veridex Llc Propagacion de celulas primarias.
US8768629B2 (en) 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
JP2010504356A (ja) 2006-09-20 2010-02-12 ザ ジョンズ ホプキンス ユニバーシティー 抗ｂ７−ｈ１抗体を用いた癌及び感染性疾患の組合せ療法
DE102006060824B4 (de) 2006-12-21 2011-06-01 Johannes-Gutenberg-Universität Mainz Nachweis von individuellen T-Zell-Reaktionsmustern gegen Tumor-assoziierte Antigene (TAA) in Tumorpatienten als Basis für die individuelle therapeutische Vakzinierung von Patienten
EP2133365B1 (en) 2006-12-27 2017-05-17 Emory University Compositions and methods for the treatment of infections and tumors
US8140270B2 (en) 2007-03-22 2012-03-20 National Center For Genome Resources Methods and systems for medical sequencing analysis
US8877206B2 (en) 2007-03-22 2014-11-04 Pds Biotechnology Corporation Stimulation of an immune response by cationic lipids
WO2008156712A1 (en) 2007-06-18 2008-12-24 N. V. Organon Antibodies to human programmed death receptor pd-1
WO2009046738A1 (en) * 2007-10-09 2009-04-16 Curevac Gmbh Composition for treating lung cancer, particularly of non-small lung cancers (nsclc)
EP2060583A1 (en) 2007-10-23 2009-05-20 Ganymed Pharmaceuticals AG Identification of tumor-associated markers for diagnosis and therapy
CN101980707B (zh) 2008-03-24 2015-05-20 4Sc股份有限公司 新的取代的咪唑并喹啉化合物
US9789129B2 (en) 2008-04-17 2017-10-17 Pds Biotechnology Corporation Stimulation of an immune response by enantiomers of cationic lipids
JP5268444B2 (ja) * 2008-06-23 2013-08-21 株式会社日立ハイテクノロジーズ 単分子リアルタイムシーケンス装置，核酸分析装置及び単分子リアルタイムシーケンス方法
WO2010037408A1 (en) 2008-09-30 2010-04-08 Curevac Gmbh Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
EP2337795A2 (en) * 2008-10-01 2011-06-29 Dako Denmark A/S Mhc multimers in cancer vaccines and immune monitoring
WO2010042919A2 (en) 2008-10-11 2010-04-15 Government Of The U.S.A. , As Represented By The Secretary, Dpartmetn Of Health And Human Services Method of making a vaccine
JP5520961B2 (ja) 2008-11-28 2014-06-11 エモリー ユニバーシティ 感染症および腫瘍を処置するための方法
DE102008061522A1 (de) 2008-12-10 2010-06-17 Biontech Ag Verwendung von Flt3-Ligand zur Verstärkung von Immunreaktionen bei RNA-Immunisierung
EP3165234B1 (de) 2009-07-31 2019-04-03 ethris GmbH Rna mit einer kombination aus unmodifizierten und modifizierten nucleotiden zur proteinexpression
GB201006360D0 (en) 2010-04-16 2010-06-02 Immatics Biotechnologies Gmbh Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development
DK3023788T3 (da) * 2010-05-14 2020-04-27 Massachusetts Gen Hospital Sammensætninger af tumorspecifikke neoantigener til anvendelse ved behandling af tumorer
ES3005233T3 (en) 2010-10-01 2025-03-14 Modernatx Inc Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
DE12722942T1 (de) 2011-03-31 2021-09-30 Modernatx, Inc. Freisetzung und formulierung von manipulierten nukleinsäuren
DE102011102734A1 (de) 2011-05-20 2012-11-22 WMF Württembergische Metallwarenfabrik Aktiengesellschaft Vorrichtung zum Aufschäumen von Milch, Getränkebereiter mit dieser Vorrichtung und Verfahren zum Aufschäumen von Milch
LT3473267T (lt) 2011-05-24 2021-11-25 BioNTech SE Individualizuotos vakcinos nuo vėžio
PL2714071T3 (pl) 2011-05-24 2019-12-31 Biontech Rna Pharmaceuticals Gmbh Zindywidualizowane szczepionki przeciwrakowe
WO2012159643A1 (en) 2011-05-24 2012-11-29 Biontech Ag Individualized vaccines for cancer
EP2771349B1 (en) 2011-09-16 2020-02-26 Iogenetics, LLC. Bioinformatic processes for determination of peptide binding
RU2648950C2 (ru) 2011-10-03 2018-04-02 Модерна Терапьютикс, Инк. Модифицированные нуклеозиды, нуклеотиды и нуклеиновые кислоты и их применение
AU2012352180A1 (en) 2011-12-16 2014-07-31 Moderna Therapeutics, Inc. Modified nucleoside, nucleotide, and nucleic acid compositions
WO2013106496A1 (en) 2012-01-10 2013-07-18 modeRNA Therapeutics Methods and compositions for targeting agents into and across the blood-brain barrier
EP2817322B1 (en) 2012-02-20 2016-04-20 Universita' degli Studi di Milano Homo- and heterodimeric smac mimetic compounds as apoptosis inducers
US20130255281A1 (en) 2012-03-29 2013-10-03 General Electric Company System and method for cooling electrical components
WO2013151663A1 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of membrane proteins
MX364370B (es) 2012-07-12 2019-04-24 Persimmune Inc Vacunas contra el cancer personalizadas y terapias de celulas inmunes adoptivas.
BR122019025681B1 (pt) 2012-11-01 2023-04-18 Factor Bioscience Inc Método para inserir uma sequência de ácido nucleico em uma localização segura de um genoma de uma célula
HRP20220607T1 (hr) 2012-11-26 2022-06-24 Modernatx, Inc. Terminalno modificirana rna
EP2931319B1 (en) 2012-12-13 2019-08-21 ModernaTX, Inc. Modified nucleic acid molecules and uses thereof
EP2964234A4 (en) 2013-03-09 2016-12-07 Moderna Therapeutics Inc Heterologous untranslated regions for mrna
EP2968391A1 (en) 2013-03-13 2016-01-20 Moderna Therapeutics, Inc. Long-lived polynucleotide molecules
EP2971010B1 (en) 2013-03-14 2020-06-10 ModernaTX, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
WO2014160243A1 (en) 2013-03-14 2014-10-02 The Trustees Of The University Of Pennsylvania Purification and purity assessment of rna molecules synthesized with modified nucleosides
EP4279610A3 (en) 2013-03-15 2024-01-03 ModernaTX, Inc. Ribonucleic acid purification
US10077439B2 (en) 2013-03-15 2018-09-18 Modernatx, Inc. Removal of DNA fragments in mRNA production process
US10138507B2 (en) 2013-03-15 2018-11-27 Modernatx, Inc. Manufacturing methods for production of RNA transcripts
US20160017313A1 (en) 2013-03-15 2016-01-21 Moderna Therapeutics, Inc. Analysis of mrna heterogeneity and stability
WO2014144039A1 (en) 2013-03-15 2014-09-18 Moderna Therapeutics, Inc. Characterization of mrna molecules
US10590161B2 (en) 2013-03-15 2020-03-17 Modernatx, Inc. Ion exchange purification of mRNA
CN118750591A (zh) 2013-04-07 2024-10-11 博德研究所 用于个性化瘤形成疫苗的组合物和方法
WO2015014375A1 (en) 2013-07-30 2015-02-05 Biontech Ag Tumor antigens for determining cancer therapy
EP3041934A1 (en) 2013-09-03 2016-07-13 Moderna Therapeutics, Inc. Chimeric polynucleotides
EP3041938A1 (en) 2013-09-03 2016-07-13 Moderna Therapeutics, Inc. Circular polynucleotides
US9925277B2 (en) 2013-09-13 2018-03-27 Modernatx, Inc. Polynucleotide compositions containing amino acids
CA2925047C (en) 2013-09-26 2021-03-23 Biontech Ag Rna decorated particles
WO2015051173A2 (en) 2013-10-02 2015-04-09 Moderna Therapeutics, Inc Polynucleotide molecules and uses thereof
EP3052511A4 (en) 2013-10-02 2017-05-31 Moderna Therapeutics, Inc. Polynucleotide molecules and uses thereof
WO2015058780A1 (en) 2013-10-25 2015-04-30 Biontech Ag Method and kit for determining whether a subject shows an immune response
US20170173128A1 (en) 2013-12-06 2017-06-22 Moderna TX, Inc. Targeted adaptive vaccines
EP2918275B1 (en) 2013-12-13 2016-05-18 Moderna Therapeutics, Inc. Alternative nucleic acid molecules and uses thereof
JP2017507703A (ja) 2014-02-05 2017-03-23 バイオエヌテック アーゲーＢｉｏＮＴｅｃｈ ＡＧ カニューレ、注射または注入装置、およびカニューレまたは注射もしくは注入装置を使用する方法
ES3009962T3 (en) 2014-04-23 2025-03-31 Modernatx Inc Nucleic acid vaccines
WO2015172843A1 (en) 2014-05-16 2015-11-19 Biontech Diagnostics Gmbh Methods and kits for the diagnosis of cancer
WO2016062323A1 (en) 2014-10-20 2016-04-28 Biontech Ag Methods and compositions for diagnosis and treatment of cancer
EP3230458B1 (en) 2014-12-12 2020-02-19 CureVac AG Artificial nucleic acid molecules for improved protein expression
CA2966092A1 (en) 2014-12-30 2016-07-07 Curevac Ag Artificial nucleic acid molecules
WO2016155809A1 (en) 2015-03-31 2016-10-06 Biontech Rna Pharmaceuticals Gmbh Lipid particle formulations for delivery of rna and water-soluble therapeutically effective compounds to a target cell

Also Published As

Publication number Publication date
RS62497B1 (sr) 2021-11-30
CN103608033B (zh) 2016-06-15
US20220282322A1 (en) 2022-09-08
RS67093B1 (sr) 2025-09-30
MX2013013659A (es) 2014-02-27
AU2022201275A1 (en) 2022-03-17
ES2946072T3 (es) 2023-07-12
MX386793B (es) 2025-03-19
ES2897656T3 (es) 2022-03-02
JP2020128423A (ja) 2020-08-27
HRP20230443T1 (hr) 2023-09-15
NZ730355A (en) 2022-10-28
JP2023083289A (ja) 2023-06-15
AU2019229434A1 (en) 2019-10-03
WO2012159754A3 (en) 2013-06-27
NZ718326A (en) 2020-05-29
MX360823B (es) 2018-11-16
DK3892295T3 (da) 2023-05-15
RS64230B1 (sr) 2023-06-30
RU2013157150A (ru) 2015-06-27
DK4223311T3 (da) 2025-08-25
MX2020011767A (es) 2020-11-24
LT4223311T (lt) 2025-09-25
US11248264B2 (en) 2022-02-15
BR112013029834A8 (pt) 2019-05-07
PL3892295T3 (pl) 2023-07-24
FI4223311T3 (fi) 2025-08-12
LT2714071T (lt) 2019-10-10
CN105999250A (zh) 2016-10-12
BR112013029834A2 (pt) 2016-12-06
PL4223311T3 (pl) 2025-09-08
US20210164034A1 (en) 2021-06-03
ZA201306944B (en) 2015-02-25
US10738355B2 (en) 2020-08-11
DK2714071T3 (da) 2019-09-16
AU2022201275B2 (en) 2025-08-14
SMT202300161T1 (it) 2023-07-20
CN111286537A (zh) 2020-06-16
HRP20250981T1 (hr) 2025-10-24
US20140178438A1 (en) 2014-06-26
PT4223311T (pt) 2025-08-21
JP2014523406A (ja) 2014-09-11
HRP20211595T1 (hr) 2022-01-21
SI4223311T1 (sl) 2025-11-28
PT3892295T (pt) 2023-06-01
ES2746233T3 (es) 2020-03-05
JP6444171B2 (ja) 2018-12-26
AU2012261237B2 (en) 2017-06-01
LT3892295T (lt) 2023-07-10
SMT202500304T1 (it) 2025-09-12
JP2017018129A (ja) 2017-01-26
SG193553A1 (en) 2013-10-30
HUE062102T2 (hu) 2023-09-28
HUE057608T2 (hu) 2022-06-28
HUE046152T2 (hu) 2020-02-28
LT3473267T (lt) 2021-11-25
JP2025109722A (ja) 2025-07-25
AU2017213515B2 (en) 2019-07-04
PT3473267T (pt) 2021-11-02
AU2012261237A1 (en) 2013-11-14
NZ617217A (en) 2016-04-29
RU2670745C9 (ru) 2018-12-13
CN105999250B (zh) 2020-03-10
PT2714071T (pt) 2019-09-30
SG10201911616QA (en) 2020-01-30
CA2836494C (en) 2023-01-03
FI3892295T3 (fi) 2023-05-10
SI3473267T1 (sl) 2022-01-31
AU2019229434B2 (en) 2021-12-16
CN103608033A (zh) 2014-02-26
SI3892295T1 (sl) 2023-09-29
NZ742420A (en) 2022-10-28
AU2017213515A1 (en) 2017-08-31
RU2670745C2 (ru) 2018-10-25
JP7297715B2 (ja) 2023-06-26
JP2019050831A (ja) 2019-04-04
WO2012159754A2 (en) 2012-11-29
ES3038443T3 (en) 2025-10-13
CA2836494A1 (en) 2012-11-29
JP6456888B2 (ja) 2019-01-23
ES2746233T8 (es) 2020-03-13

Similar Documents

Publication Publication Date Title
ZA201306944B (en) Individualized vaccines for cancer
SG10201509549TA (en) Adjustable fracturing system
IL231043A0 (en) vaccine
GB201120860D0 (en) Cancer immunotherapy
SG10201508535RA (en) Antigen Presenting Cancer Vaccine
GB201119999D0 (en) Vaccine
SI2714071T1 (sl) Individualizirana cepiva proti raku
ZA201306245B (en) Combination vaccines
SG2014007694A (en) Radiation source
PL2729158T3 (pl) Szczepionki przeciwko Chlamydia
GB201120000D0 (en) Vaccine
GB201106630D0 (en) Cancer therapy
GB201107549D0 (en) Cancer vaccine
GB201108986D0 (en) Vaccines
GB201108984D0 (en) Vaccines
GB201108982D0 (en) Vaccines
GB201108256D0 (en) Vaccine
GB201121647D0 (en) Vaccine
IL231330A0 (en) Cancer diagnosis methods
GB201118153D0 (en) Therapies for cancers
GB201116342D0 (en) Antigen combinations
GB201109294D0 (en) Novel vaccine
GB201118220D0 (en) Cancer therapy